Cargando…

Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box

The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Pedro, Jesus, João, Santos, Sofia, Raposo, Luis R., Roma-Rodrigues, Catarina, Baptista, Pedro Viana, Fernandes, Alexandra R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331900/
https://www.ncbi.nlm.nih.gov/pubmed/26389876
http://dx.doi.org/10.3390/molecules200916852
_version_ 1783387224241340416
author Martins, Pedro
Jesus, João
Santos, Sofia
Raposo, Luis R.
Roma-Rodrigues, Catarina
Baptista, Pedro Viana
Fernandes, Alexandra R.
author_facet Martins, Pedro
Jesus, João
Santos, Sofia
Raposo, Luis R.
Roma-Rodrigues, Catarina
Baptista, Pedro Viana
Fernandes, Alexandra R.
author_sort Martins, Pedro
collection PubMed
description The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles.
format Online
Article
Text
id pubmed-6331900
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63319002019-01-24 Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box Martins, Pedro Jesus, João Santos, Sofia Raposo, Luis R. Roma-Rodrigues, Catarina Baptista, Pedro Viana Fernandes, Alexandra R. Molecules Review The majority of heterocycle compounds and typically common heterocycle fragments present in most pharmaceuticals currently marketed, alongside with their intrinsic versatility and unique physicochemical properties, have poised them as true cornerstones of medicinal chemistry. Apart from the already marketed drugs, there are many other being investigated for their promising activity against several malignancies. In particular, anticancer research has been capitalizing on the intrinsic versatility and dynamic core scaffold of these compounds. Nevertheless, as for any other promising anticancer drugs, heterocyclic compounds do not come without shortcomings. In this review, we provide for a concise overview of heterocyclic active compounds and families and their main applications in medicine. We shall focus on those suitable for cancer therapy while simultaneously addressing main biochemical modes of action, biological targets, structure-activity relationships as well as intrinsic limitation issues in the use of these compounds. Finally, considering the advent of nanotechnology for effective selective targeting of drugs, we shall discuss fundamental aspects and considerations on nanovectorization of such compounds that may improve pharmacokinetic/pharmacodynamic properties of heterocycles. MDPI 2015-09-16 /pmc/articles/PMC6331900/ /pubmed/26389876 http://dx.doi.org/10.3390/molecules200916852 Text en © 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martins, Pedro
Jesus, João
Santos, Sofia
Raposo, Luis R.
Roma-Rodrigues, Catarina
Baptista, Pedro Viana
Fernandes, Alexandra R.
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title_full Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title_fullStr Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title_full_unstemmed Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title_short Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
title_sort heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine’s tool box
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331900/
https://www.ncbi.nlm.nih.gov/pubmed/26389876
http://dx.doi.org/10.3390/molecules200916852
work_keys_str_mv AT martinspedro heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT jesusjoao heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT santossofia heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT raposoluisr heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT romarodriguescatarina heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT baptistapedroviana heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox
AT fernandesalexandrar heterocyclicanticancercompoundsrecentadvancesandtheparadigmshifttowardstheuseofnanomedicinestoolbox